Baby products linked to phthalates in infants
This article was originally published in The Rose Sheet
Executive Summary
Use of shampoo, lotion and powder for babies are linked to higher levels of phthalates in infants in study published Feb. 4 in the journal Pediatrics. The study, "Baby Care Products: Possible Sources of Infant Phthalate Exposure," by Sheela Sathyanarayana, MD, et al., University of Washington, tested urinary concentrations of nine phthalates in 163 infants. All samples contained at least one phthalate at measurable levels, and 80% had at least seven types of the chemical. Skin absorption is cited as a major route of exposure, though children can be exposed to phthalates via multiple sources. Infants younger than eight months are at higher risk for reproductive and developmental toxicity caused by the chemical due to their immature metabolic systems and higher body-surface-area-to-volume ratio than that of older children, researchers say. They recommend that parents limit the number of baby-care products they use in order to minimize exposure...
You may also be interested in...
Beauty Firms Should Act Now To Obviate Legislation Later, Lauder VP Says
Openness and consumer engagement are needed from the personal-care industry to assuage the public's fears and stave off further regulation like the costly Registration, Evaluation, Authorization and Restriction of Chemicals program in Europe, according to Estee Lauder's Harvey Gedeon
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.